First-in-Human Study of BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody in Patients With Neuromyelitis Optica Spectrum Disorders

Overview

Journal CNS Neurosci Ther

Specialties Neurology
Pharmacology

Date 2024 Nov 26

PMID 39592888

Authors

Hai Yu

Yuancheng Chen

Yunpeng Qi

Haijing Yang

Guoying Cao

Wenbo Yang

Size Li

Xiaolei Yang

Hai Wang

Jing Zhang

Xiangjun Chen

Affiliations

Soon will be listed here.

Abstract

Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is a rare debilitating autoimmune disease of the central nervous system (CNS). This is the first-in-human dose-escalation Phase I clinical study of BAT4406F, an antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced fully humanized anti-CD20 monoclonal antibody, in Chinese NMOSD patients.

Patients And Methods: Using a "3 + 3" design and based on the planned algorithm of dose escalation, the enrolled NMOSD patients were sequentially assigned to one of the five dose-escalation cohorts of BAT4406F with a single intravenous dose, and were then followed for a 6-month observation period. The maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), safety, pharmacokinetics (PK), pharmacodynamics, and immunogenicity of BAT4406F were investigated, and the efficacy of BAT4406F in NMOSD was also preliminarily explored.

Results: Fifteen Chinese NMOSD patients were enrolled to receive BAT4406F of escalated doses ranging from 20 to 750 mg. No subjects experienced DLT at the studied doses. BAT4406F injection exhibited favorable safety, with most of the adverse events (AE) of CTCAE Grade 1 or 2 in severity, and no Grade ≥ 3 adverse drug reactions (ADR) or serious adverse reactions occurred in any subjects. With the dose increase of BAT4406F, the maximum plasma concentration (C), area under concentration-time curve from 0 to the last measurable timepoint (AUC) and area under concentration-time curve from 0 to infinity (AUC) showed an increasing trend, whereas the mean clearance (CL), terminal elimination rate (λ), and apparent volume of distribution (V) decreased. The mean elimination half-life (T) was ranged from 9.0-16.4 days. PK profile of BAT4406F was generally nonlinear. BAT4406F led to a rapid and significant B-cell depletion in all dose groups. Single administration of 500 mg or 750 mg maintains the CD19 B lymphocyte count below 10/μL within the whole 6-month observation period. Three subjects were antidrug antibody (ADA) positive and all of them were neutralizing antibody (NAb)-negative. On day 99/180 postdose, several groups had decreased expanded disability status scale (EDSS) scores compared to baseline. During the observation period, NMOSD relapse occurred in two patients (13.3%) and the other 13 (86.7%) subjects remained relapse free.

Conclusion: BAT4406F was well tolerated at doses up to 750 mg and showed an expected pharmacodynamic effect of significant and long-term depletion of CD19 B lymphocytes. It has also shown preliminary evidence of activity in NMOSD maintenance treatment, warranting further investigations.

Trial Registration: ClinicalTrials.gov identifier: NCT04146285.

References

Jarius S, Frederikson J, Waters P, Paul F, Akman-Demir G, Marignier R . Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci. 2010; 298(1-2):158-62. DOI: 10.1016/j.jns.2010.07.011. View

Sellner J, Boggild M, Clanet M, Hintzen R, Illes Z, Montalban X . EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010; 17(8):1019-32. DOI: 10.1111/j.1468-1331.2010.03066.x. View

Pellkofer H, Krumbholz M, Berthele A, Hemmer B, Gerdes L, Havla J . Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011; 76(15):1310-5. DOI: 10.1212/WNL.0b013e3182152881. View

Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D . Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris). 2018; 174(4):255-264. DOI: 10.1016/j.neurol.2017.11.005. View

Weinshenker B, Wingerchuk D, Vukusic S, Linbo L, Pittock S, Lucchinetti C . Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006; 59(3):566-9. DOI: 10.1002/ana.20770. View

Vogel W . Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010; 14(2):E10-21. DOI: 10.1188/10.CJON.E10-E21. View

Levy G . Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther. 1994; 56(3):248-52. DOI: 10.1038/clpt.1994.134. View

Gibiansky E, Gibiansky L, Carlile D, Jamois C, Buchheit V, Frey N . Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL. CPT Pharmacometrics Syst Pharmacol. 2014; 3:e144. PMC: 4474170. DOI: 10.1038/psp.2014.42. View

Kang S, Saif M . Infusion-related and hypersensitivity reactions of monoclonal antibodies used to treat colorectal cancer--identification, prevention, and management. J Support Oncol. 2007; 5(9):451-7. View

10.

Rozman S, Grabnar I, Novakovic S, Mrhar A, Novakovic B . Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol. 2017; 83(8):1782-1790. PMC: 5510082. DOI: 10.1111/bcp.13271. View

11.

Greenberg B, Graves D, Remington G, Hardeman P, Mann M, Karandikar N . Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler. 2012; 18(7):1022-6. DOI: 10.1177/1352458511432896. View

12.

Bennett J, Lam C, Kalluri S, Saikali P, Bautista K, Dupree C . Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009; 66(5):617-29. PMC: 3180961. DOI: 10.1002/ana.21802. View

13.

Yan L, Kimko H, Wang B, Cimbora D, Katz E, Rees W . Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis. Clin Pharmacokinet. 2021; 61(3):387-400. PMC: 8891208. DOI: 10.1007/s40262-021-01071-5. View

14.

Jarius S, Paul F, Weinshenker B, Levy M, Kim H, Wildemann B . Neuromyelitis optica. Nat Rev Dis Primers. 2020; 6(1):85. DOI: 10.1038/s41572-020-0214-9. View

15.

Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2):177-89. PMC: 4515040. DOI: 10.1212/WNL.0000000000001729. View

16.

Dua P, Hawkins E, van der Graaf P . A Tutorial on Target-Mediated Drug Disposition (TMDD) Models. CPT Pharmacometrics Syst Pharmacol. 2015; 4(6):324-37. PMC: 4505827. DOI: 10.1002/psp4.41. View

17.

Kim S, Kim W, Li X, Jung I, Kim H . Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol. 2011; 68(11):1412-20. DOI: 10.1001/archneurol.2011.154. View

18.

Papp V, Magyari M, Aktas O, Berger T, Broadley S, Cabre P . Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology. 2020; 96(2):59-77. PMC: 7905781. DOI: 10.1212/WNL.0000000000011153. View

19.

Golay J, Da Roit F, Bologna L, Ferrara C, Leusen J, Rambaldi A . Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013; 122(20):3482-91. DOI: 10.1182/blood-2013-05-504043. View

20.

Bensalem A, Cartron G, Specks U, Mulleman D, Gyan E, Cornec D . The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition. Clin Pharmacokinet. 2021; 61(3):423-437. DOI: 10.1007/s40262-021-01081-3. View